DWTX
Dogwood
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DWTX
Dogwood Therapeutics, Inc.
A development-stage biotechnology company developing novel antiviral therapeutics
44 Milton Avenue, Alpharetta, GA 30009
--
Dogwood Therapeutics, Inc., originally incorporated in Alabama on February 28, 2012, was later changed to a Nevada company. The company is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with abnormal immune responses triggered by viruses, such as fibromyalgia (" FM ").
Company Financials
EPS
DWTX has released its 2024 Q4 earnings. EPS was reported at -6.29, versus the expected -1.29, missing expectations. The chart below visualizes how DWTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
